DE03742226T1 - Verwendung von anecortaveacetat zum schutz der sehkraft von patienten mit altersbedingter makulardegeneration - Google Patents

Verwendung von anecortaveacetat zum schutz der sehkraft von patienten mit altersbedingter makulardegeneration Download PDF

Info

Publication number
DE03742226T1
DE03742226T1 DE03742226T DE03742226T DE03742226T1 DE 03742226 T1 DE03742226 T1 DE 03742226T1 DE 03742226 T DE03742226 T DE 03742226T DE 03742226 T DE03742226 T DE 03742226T DE 03742226 T1 DE03742226 T1 DE 03742226T1
Authority
DE
Germany
Prior art keywords
depot
compound
anecortave acetate
administered
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE03742226T
Other languages
German (de)
English (en)
Inventor
A. Janice JERDAN
Patricia Zilliox
M. Stella ROBERTSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE03742226T1 publication Critical patent/DE03742226T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE03742226T 2002-08-05 2003-06-26 Verwendung von anecortaveacetat zum schutz der sehkraft von patienten mit altersbedingter makulardegeneration Pending DE03742226T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05
US401220P 2002-08-05
PCT/US2003/020154 WO2004012742A1 (en) 2002-08-05 2003-06-26 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Publications (1)

Publication Number Publication Date
DE03742226T1 true DE03742226T1 (de) 2006-03-09

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE03742226T Pending DE03742226T1 (de) 2002-08-05 2003-06-26 Verwendung von anecortaveacetat zum schutz der sehkraft von patienten mit altersbedingter makulardegeneration

Country Status (17)

Country Link
US (2) US20040127472A1 (https=)
EP (1) EP1539182A4 (https=)
JP (1) JP2005535691A (https=)
KR (1) KR20050026510A (https=)
CN (1) CN1674913A (https=)
AR (1) AR040599A1 (https=)
AU (1) AU2003281817A1 (https=)
BR (1) BR0313546A (https=)
CA (1) CA2494211A1 (https=)
DE (1) DE03742226T1 (https=)
ES (1) ES2244361T1 (https=)
MX (1) MXPA05000773A (https=)
PL (1) PL375024A1 (https=)
RU (1) RU2322239C2 (https=)
TW (1) TW200410699A (https=)
WO (1) WO2004012742A1 (https=)
ZA (1) ZA200500731B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
MXPA05008396A (es) * 2003-02-20 2006-03-30 Alcon Inc Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica.
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
RU2051651C1 (ru) * 1988-07-07 1996-01-10 Институт химии поверхности АН Украины Основа для глазных капель
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
AR040599A1 (es) 2005-04-13
BR0313546A (pt) 2005-07-12
ZA200500731B (en) 2006-08-30
RU2005106234A (ru) 2005-08-10
KR20050026510A (ko) 2005-03-15
US20060166956A1 (en) 2006-07-27
AU2003281817A1 (en) 2004-02-23
MXPA05000773A (es) 2005-04-19
CN1674913A (zh) 2005-09-28
TW200410699A (en) 2004-07-01
WO2004012742A1 (en) 2004-02-12
US20040127472A1 (en) 2004-07-01
PL375024A1 (en) 2005-11-14
ES2244361T1 (es) 2005-12-16
JP2005535691A (ja) 2005-11-24
CA2494211A1 (en) 2004-02-12
EP1539182A1 (en) 2005-06-15
EP1539182A4 (en) 2010-01-20
RU2322239C2 (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
DE03742226T1 (de) Verwendung von anecortaveacetat zum schutz der sehkraft von patienten mit altersbedingter makulardegeneration
Risner et al. A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion.
US5849763A (en) Use of levobupivacaine as an anesthetic agent
EP1210076A2 (de) Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid
AU730390B2 (en) The use of levobupivacaine in facial surgery
US20220072011A1 (en) Treatments of accumulated fat with deoxycholic acid and salts thereof
EP1397138B1 (de) WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
JP2005535691A5 (https=)
EP1814532A2 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2008025543A1 (en) Pharmaceutical compositions for the treatment of fungal infections
NL8102369A (nl) Preparaat van een antimicrobisch middel en werkwijze ter bereiding daarvan.
RU2006124557A (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
EP0069075B1 (en) Pharmaceutical preparation for treating glaucoma and ocular hypertension
DE10163421A1 (de) Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
EP1156830B1 (de) Verwendung einer öl-in-wasser-emulsion zur herstellung eines arzneimittels
AT504041A1 (de) Verwendung von den enzymatischen abbau von endogenen opioid-neuropeptiden hemmenden substanzen
DE60024408T2 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE2305209A1 (de) Pharmazeutisches praeparat
Waechter et al. A comparison between topical and infiltrative bupivacaine and intravenous meperidine for postoperative analgesia after inguinal herniorrhaphy
US20050032840A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
US5665731A (en) Method and composition for treating with a vasodilator inflammation, bone loss and detachment of teeth as associated with periodontal
CA3241841A1 (en) Compositions and methods for covid-19 treatment
MXPA99008056A (en) The use of levobupivacaine or ropivacaine in treating migraine